Enrollment wraps in pivotal Phase 3 back pain trial, setting Mesoblast up for mid-2027 data
MESO sits 50% above its 52-week low of $10.805.
Summary
Enrollment of 300 patients is complete in the pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, a potential blockbuster indication. Top-line results are expected in mid-2027.
Key Events · Product Development and Regulatory · MESO
-
Pivotal Trial Enrollment Complete
The MSB-DR004 Phase 3 trial of rexlemestrocel-L for chronic low back pain has now treated at least 300 patients, reaching the enrollment target required for adequate statistical power.
-
Blockbuster Revenue Potential
With over 7 million U.S. patients in the addressable market, even single-digit penetration could drive peak year revenue exceeding US$10 billion.
-
Regulatory Pathway De-Risked
Rexlemestrocel-L holds FDA RMAT designation, which enables priority review upon BLA filing. Both the trial design and primary endpoint were previously agreed with the FDA.
-
Top-Line Results Expected Mid-2027
A data readout is anticipated in mid-CY2027, once the last treated patient completes 12 months of follow-up.
Analysis · MESO · Life Sciences
Hitting the 300-patient enrollment target in the pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain marks a major de-risking step for a program that could unlock a >US$10 billion peak revenue opportunity. With the trial now fully powered to detect a meaningful reduction in pain, top-line results are on track for mid-2027. The achievement adds to a string of positive developments—strong Ryoncil sales, a $50 million non-dilutive debt facility, and FDA acceptance of a BLA for another indication—that underscore the company's execution momentum.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MESO was trading at $16.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.81 to $21.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.